Gefitinib accumulation in glioblastoma tissue

Cancer Biology and Therapy

Volumn 5, Issue 5, 2006, Pages 483-484

  Hofer, Silvia ^a,c   Frei, Karl ^a   Rutz, Hans Peter ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b PAUL SCHERRER INSTITUTE   (Switzerland)

^c USZ   (Switzerland)

Author keywords

EGFR; Gefitinib; Glioblastoma multiforme; Tissue concentration

Indexed keywords

CYTOCHROME P450 3A4; GEFITINIB;

ARTICLE; BIOACCUMULATION; CANCER CELL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DIFFUSION; DRUG ELIMINATION; DRUG METABOLISM; DRUG SOLUBILITY; DRUG TUMOR LEVEL; ENZYME ACTIVITY; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; MOLECULAR SIZE; REOPERATION; THERMODYNAMICS; UNSPECIFIED SIDE EFFECT;

EID: 33646774003     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.5.5.2653     Document Type: Article

References (37)

1. Little JB. Repair of sub-lethal and potentially lethal radiation damage in plateau phase cultures of human cells. Nature 1969; 224:804-6.
2. Weichselbaum RR. The role of DNA repair processes in the response of human tumors to fractionated radiotherapy. Int J Radiat Oncol Biol Phys 1984; 10:1127-34.
3. Chaney SG, Sancar A. DNA repair: enzymatic mechanisms and relevance to drug response. J Natl Cancer Inst 1996; 88:1346-60.
4. Moulder JE, Rockwell S. Tumor hypoxia: its impact on cancer therapy. Cancer Metastasis Rev 1987; 5:313-41.
5. Vaupel P, Mayer A. Hypoxia and anemia: effects on tumor biology and treatment resistance. Transfus Clin Biol 2005; 12:5-10.
6. Rutz HP. Effects of corticosteroid use on treatment of solid tumours. Lancet 2002; 360:1969-70.
7. Rutz HP, Herr I. Glucocorticoid administration in antiemetic therapy: Is it safe? Cancer 2005; 103:2656-7.
8. Viktorsson K, Lewensohn R, Zhivotovsky B. Apoptotic pathways and therapy resistance in human malignancies. Adv Cancer Res 2005; 94:143-96.
9. Rutz HP, Herr I. Interference of glucocorticoids with apoptosis signaling and host-tumor interactions. Cancer Biol Ther 2004; 3:715-8.
10. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ, Riggs BL, Horvath S, Liau LM, Cavenee WK, Rao PN, Beroukhim R, Peck TC, Lee JC, Sellers WR, Stokoe D, Prados M, Cloughesy TF, Sawyers CL, Mischel PS. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005; 353:2012-24.
11. Giaccone G, Rodriguez JA. EGFR inhibitors: what have we learned from the treatment of lung cancer? Nat Clin Pract Oncol 2005; 2:554-61.
12. Scripture CD, Sparreboom A, Figg WD. Modulation of cytochrome P450 activity: implications for cancer therapy. Lancet Oncol 2005; 6:780-9.
13. Swaisland HC, Ranson M, Smith RP, Leadbetter J, Laight A, McKillop D, Wild MJ. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol. Clin Pharmacokinet 2005; 44:1067-81.
14. Regina A, Demeule M, Laplante A, Jodoin J, Dagenais C, Berthelet F, Moghrabi A, Beliveau R. Multidrug resistance in brain tumors: roles of the blood-brain barrier. Cancer Metastasis Rev 2001; 20:13-25.
15. Loscher W, Potschka H. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx 2005; 2:86-98.
16. Jain RK. Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Rev 1990; 9:253-66.
17. Rutz HP. Hydrodynamic consequences of glycolysis: thermodynamic basis and clinical relevance. Cancer Biol Ther 2004; 3:812-5.
18. Sengupta S, Eavarone D, Capila I, Zhao G, Watson N, Kiziltepe T, Sasisekharan R. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature 2005; 436(7050):568-72.
19. Ling V. Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Chemother Pharmacol 1997; 40 Suppl:S3-8.
20. Spiegl-Kreinecker S, Buchroithner J, Elbling L, Steiner E, Wurm G, Bodenteich A, Fischer J, Micksche M, Berger W. Expression and functional activity of the ABC-transporter proteins P-glycoprotein and multidrug-resistance protein 1 in human brain tumor cells and astrocytes. J Neurooncol 2002; 57:27-36.
21. Leonard GD, Fojo T, Bates SE. The role of ABC transporters in clinical practice. Oncologist 2003; 8:411-24.
22. Jain RK. The next frontier of molecular medicine: delivery of therapeutics. Nat Med 1998; 4:655-7.
23. Primeau AJ, Rendon A, Hedley D, Lilge L, Tannock IF. The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors. Clin Cancer Res 2005; 11:8782-8.
24. McKillop D, Partridge EA, Kemp JV, Spence MP, Kendrew J, Barnett S, Wood PG, Giles PB, Patterson AB, Bichat F, Guilbaud N, Stephens TC. Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor. Mol Cancer Ther 2005; 4:641-9.
25. Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999; 82:241-50.
26. Grunwald V, Hidalgo M. Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Natl Cancer Inst 2003; 95:851-67.
27. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005; 5:341-54.
28. Barber TD, Vogelstein B, Kinzler KW, Velculescu VE. Somatic mutations of EGFR in colorectal cancers and glioblastomas. N Engl J Med 2004; 351:2883.
29. Marie Y, Carpentier AF, Omuro AM, Sanson M, Thillet J, Hoang-Xuan K, Delattre JY. EGFR tyrosine kinase domain mutations in human gliomas. Neurology 2005; 64:1444-5.
30. Smith JS, Tachibana I, Passe SM, Huntley BK, Borell TJ, Iturria N, O'Fallon JR, Schaefer PL, Scheithauer BW, James CD, Buckner JC, Jenkins RB. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 2001; 93:1246-56.
31. Friedman HS, Bigner DD. Glioblastoma multiforme and the epidermal growth factor receptor. N Engl J Med 2005; 353:1997-9.
32. Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, Wikstrand CJ, Van Duyn LB, Dancey JE, McLendon RE, Kao JC, Stenzel TT, Ahmed Rasheed BK, Tourt-Uhlig SE, Herndon JE, 2nd, Vredenburgh JJ, Sampson JH, Friedman AH, Bigner DD, Friedman HS. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 2004; 22:133-42.
33. Wolf M, Swaisland H, Averbuch S. Development of the novel biologically targeted anti-cancer agent gefitinib: determining the optimum dose for clinical efficacy. Clin Cancer Res 2004; 10:4607-13.
34. Culy CR, Faulds D. Gefitinib. Drugs 2002; 62:2237-48; discussion 2249-50.
35. Zhao M, Hartke C, Jimeno A, Li J, He P, Zabelina Y, Hidalgo M, Baker SD. Specific method for determination of gefitinib in human plasma, mouse plasma and tissues using high performance liquid chromatography coupled to tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 819:73-80.
36. Ranson M, Hammond LA, Ferry D, Kris M, Tullo A, Murray PI, Miller V, Averbuch S, Ochs J, Morris C, Feyereislova A, Swaisland H, Rowinsky EK. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 2002; 20:2240-50.
37. Waterhouse RN. Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents. Mol Imaging Biol 2003; 5:376-89.